Taisho Pharmaceutical Co., Ltd.

Yves E M Van Roosbroeck

Atsuro Nakazato

Taketoshi Okubo

Dai Nozawa

Tomoko Tamita

Ludo E J Kennis

Jean-Pierre A M Bongartz

Mikako Yamaguchi

Frans M A Van Den Keybus

Marcel G M Luyckx

Robert J M Hendrickx

Marcel F L De Bruyn

An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved. 

Pyrrolopyridine derivatives substituted with cyclic amino group

Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group

Growing community of inventors

Beerse, Belgium

Yves E M Van Roosbroeck